Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) shareholders (or potential shareholders) will be happy to see that the CEO & Director, Peter Hecht, recently bought a whopping US$1.7m worth of stock, at a price of US$2.43. That purchase boosted their holding by 309%, which makes us wonder if the move was inspired by quietly confident deeply-felt optimism.

View our latest analysis for Cyclerion Therapeutics

Cyclerion Therapeutics Insider Transactions Over The Last Year

In fact, the recent purchase by Peter Hecht was the biggest purchase of Cyclerion Therapeutics shares made by an insider individual in the last twelve months, according to our records. That means that an insider was happy to buy shares at around the current price of US$2.76. Of course they may have changed their mind. But this suggests they are optimistic. If someone buys shares at well below current prices, it's a good sign on balance, but keep in mind they may no longer see value. Happily, the Cyclerion Therapeutics insiders decided to buy shares at close to current prices.

In the last twelve months insiders purchased 823.00k shares for US$2.0m. But they sold 20.11k shares for US$61k. In total, Cyclerion Therapeutics insiders bought more than they sold over the last year. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

Cyclerion Therapeutics is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Insider Ownership of Cyclerion Therapeutics

For a common shareholder, it is worth checking how many shares are held by company insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Our data suggests Cyclerion Therapeutics insiders own 2.7% of the company, worth about US$2.5m. We consider this fairly low insider ownership.

So What Do The Cyclerion Therapeutics Insider Transactions Indicate?

The recent insider purchase is heartening. We also take confidence from the longer term picture of insider transactions. But on the other hand, the company made a loss during the last year, which makes us a little cautious. While the overall levels of insider ownership are below what we'd like to see, the history of transactions imply that Cyclerion Therapeutics insiders are reasonably well aligned, and optimistic for the future. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Cyclerion Therapeutics. Our analysis shows 5 warning signs for Cyclerion Therapeutics (1 doesn't sit too well with us!) and we strongly recommend you look at them before investing.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.